MARKET

INCY

INCY

Incyte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

96.93
-0.32
-0.33%
After Hours: 96.93 0 0.00% 16:45 08/07 EDT
OPEN
97.25
PREV CLOSE
97.25
HIGH
98.35
LOW
95.93
VOLUME
760.54K
TURNOVER
--
52 WEEK HIGH
110.37
52 WEEK LOW
62.48
MARKET CAP
21.07B
P/E (TTM)
-106.3762
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average INCY stock price target is 105.73 with a high estimate of 132.00 and a low estimate of 87.00.

EPS

INCY News

More
NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment
The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s remdesivir with Merck KGaA's interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,0
MarketWatch · 1d ago
Incyte Earnings Soar 65%, Easily Beating Views
Incyte earnings and revenue rose much more than expected. The biotech reaffirmed guidance. INCY stock was not yet active early Tuesday.
Investor's Business Daily · 4d ago
Incyte Corp (INCY) Q2 2020 Earnings Call Transcript
INCY earnings call for the period ending June 30, 2020.
Motley Fool · 4d ago
Incyte beats Q2 consesus; Jakafi sales +16% with guidance maintained
Incyte (INCY) Q2 results: Revenues: $688M (+29.8%); Jakafi: $473.7M (+16%); Iclusig: $22.8M (-7%); Jakavi product royalty: $66.2M (+16%); Olumiant product
seekingalpha · 4d ago
Incyte EPS beats by $0.37, beats on revenue
Incyte (NASDAQ:INCY): Q2 Non-GAAP EPS of $1.24 beats by $0.37; GAAP EPS of $1.32 beats by $0.65. Revenue of $688.04M (+29.8% Y/Y) beats by $70.49M. Jakafi
seekingalpha · 4d ago
Incyte shares are trading lower after the company reported its Q2 earnings results.
Benzinga · 4d ago
Incyte (INCY) Beats on Q2 Earnings and Sales on Strong Jakafi
Incyte (INCY) easily surpasses earnings and sales expectations in the second quarter as lead drug, Jakafi, reports strong growth.
Zacks · 4d ago
Dow Jones Today Dips, Nasdaq Fights To Extend Streak; Take-Two, SolarEdge, AMD Rocket
Take-Two, Inphi and Incyte rallied Tuesday, but stock futures dipped as the Dow Jones looked toward Disney's after-hours report.
Investor's Business Daily · 4d ago

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About INCY

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
More

Webull offers kinds of Incyte Corporation stock information, including NASDAQ:INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.